HeartSciences | Company

About HeartSciences

HeartSciences is advancing the field of electrocardiography through the use of wavelet signal processing and artificial intelligence to develop next-generation ECG technology to provide valuable new insights and information that focus on the early detection of heart disease. HeartSciences seeks to bridge today’s “diagnostic gap” in cardiac care by providing front line, low-cost, effective solutions that assist in the early detection of heart disease in at-risk patients.

Formed in 2008, HeartSciences (formerly known as Heart Test Laboratories) is a privately held medical technology company located in the Dallas-Fort Worth metroplex, the largest economic area in the Southern United States. HeartSciences’ MyoVista wavECG Device benefits from more than ten years of research and development to enable the early detection of heart disease to fundamentally improve the ability of an ECG to detect structural and ischemic heart disease.

The MyoVista^® Wavelet ECG (wavECG™) Cardiac Testing Device applies proprietary use of Continuous Wavelet Transform (CWT) signal processing and represents HeartSciences first product release from years of research and development.

The MyoVista Device is not FDA cleared and is not available in the United States.

Mission

Enabling accurate, affordable screening for the early detection of heart disease.

The Problem

Heart Disease Is the Leading Cause of Death Worldwide

Closing the Diagnostic Gap requires more effective low-cost frontline tools for Heart Disease Screening and Testing

Partial List of Cardiac Testing Methods

Conventional ECGs are typically used for symptomatic patients for diagnostic evaluation of chest pain.

ECG based stress test – Higher cost but provides improved sensitivity to ischemia over resting ECG.

CT Scan – May be used with or without contract media, too expensive for frontline screening.

Echocardiogram – Uses Doppler acoustical to evaluate structural and mechanical properties of the heart.

Nuclear Stress Test – Commonly used noninvasive method for detecting coronary artery disease.

Angiogram – Invasive diagnostic evaluation of coronary artery disease (Gold Standard).

Conventional ECG – Lack of Innovation

The MyoVista wavECG Device provides low-cost advanced testing to assist in the assessment of heart disease.

The MyoVista wavECG Device provides advanced testing to help detect cardiac disease, the leading cause of death and the largest disease management spend in healthcare.

Effective testing can help shift focus to earlier lower cost treatments and better patient outcomes.

Targeting the Diagnostic gap – The MyoVista wavECG Device helps to address a lack of high-quality tools for low-cost heart testing.

The MyoVista wavECG Device is a simple, non-invasive, electrophysiology-based medical device with an innovative and intuitive user interface.

Our Mission: Enabling accurate, affordable screening for the early detection of heart disease

The MyoVista wavECG Device uses additional analysis of the ECG signal using Wavelet Signal Processing.

Wavelet Signal Processing is a well-known method allowing for spectral analysis of a signal.

MyoVista wavECG Technology uses innovative patented methods of signal analysis.

MyoVista wavECG Technology analyzes the ECG signal using conventional and new data parameters generated from signal processing.

Ongoing research and development at HeartSciences focuses on delivering on our mission statement.

Incorporates Conventional ECG

Produces conventional ECG tracing with Glasgow Interpretive Analysis and proprietary MyoVista wavECG Information reporting.

Familiar 12-lead ECG lead placement – no change in clinical workflow.

Provides new information related to the acquired ECG signal using wavelet signal processing.

Provides additional information using wavelet signal processing related to patient risk of Heart Disease.

Leadership

News and Events

Investors Portal Login

HeartSciences enables accurate, affordable screening for the early detection of heart disease. The MyoVista^® Wavelet ECG (wavECG™) Device advances cardiac screening bridging the “diagnostic gap”, detecting cardiac dysfunction. The MyoVista Device is a low cost, easy to adopt test for asymptomatic and symptomatic patients.

MyoVista- The Power of Wavelet Signal Processing.

Careers

To submit a resume and coverletter please send documents to careers@heartsciences.com